COVID-19 vaccine effectiveness
(Randomized evidence)

Search studies

Search by Vaccine name Author Registration number
Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04611802
Novavax
Dunkle L M, N Engl J Med, 2021 ()

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 3
Healthy adults in 113 sites in the USA and 6 in Mexico N=29949
Some concerns
Details

Full description

NCT04368988
Novavax
Formica N, PLoS Med, 2021 ()

Full text
Commentary
Protein subunit

NVX-CoV2373 5mcg D0/21

NVX-CoV2373 5mcg D0/Placebo D21

NVX-CoV2373 25mcg D0/21

NVX-CoV2373 25mcg D0/Placebo D21

Placebo D0/D21

RCT
Phase 2
Healthy adults (stable comorbidities permitted) aged 18-84 years at 17 centers in Australia and USA N=1288
Some concerns
Details

Full description

NCT04583995; EudraCT 2020-004123-16
Novavax
Heath P, N Engl J Med, 2021 ()

Full text
Commentary
Protein subunit

NVX-CoV2373 5 mcg D0/21

Placebo D0/21

RCT
Phase 3
Adults 18 to 84 years old who were healthy or had stable chronic medical conditions with no history of COVID-19 at 33 centres in the UK. N=15187
Some concerns
Details

Full description

NCT04368988
Novavax
Keech C, N Engl J Med, 2020 ()

Full text
Commentary
Protein subunit

NVX-CoV2373 25mcg D0/21

NVX-CoV2373 5mcg/Matrix-M1 50 mcg D0/21

NVX-CoV2373 25mcg/Matrix-M1 50 mcg D0/21

NVX-CoV2373 25mcg/Matrix-M1 50 mcg D0/ Placebo D21

Placebo D0/21

RCT
Phase 1
Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. N=134
Some concerns
Details

Full description

NCT04368988
Novavax
Mallory R, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

NVX-CoV2373 boost

NVX-CoV2373

NVX-CoV2373

Placebo

RCT
Phase 2
Healthy adults (stable comorbidities and confirmed COVID-19 with mild symptoms permitted) who had received 2 doses NVX-CoV2373 or placebo in a trial at 17 centers in Australia and USA N=383 N/A

Full description

NCT04533399; PACTR202009726132275
Novavax
Shinde V, N Engl J Med, 2021 ()

Full text
Commentary
Protein subunit

5mcg NVX-CoV2373 with 50 mcg Matrix-M1 adjuvant

Placebo

RCT
Phase 2
HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa N=4406
Some concerns
Details

Full description